Fengliang Zhang1, Hua Kang2, Qing Xu1. 1. Department of General Surgery, Capital Medical University School of Rehabilitation, Beijing Charity Hospital, China Rehabilitation Research Center Beijing 100068, P. R. China. 2. Department of General Surgery, Xuanwu Hospital, Capital Medical University Beijing 100068, P. R. China.
Abstract
OBJECTIVE: Stromal cell derived factor-1 (SDF-1) is closely related to the biological characteristics of breast cancer. The aim of this article is to investigate if estrogen affects the biological characteristics of breast cancer via affecting secretion of SDF-1. METHODS: The breast cancer cell lines MCF-7 and MDA-MB-231 used in this study were divided into control group, estrogen group and estrogen plus estrogen receptor (ER) antagonist group. These groups were treated with different concentrations of 17-β estradiol or the same concentration of 17-β estradiol for different times, respectively. Enzyme-linked immunosorbent assay and semi-quantitative reverse transcriptase polymerase chain reaction were performed. RESULTS: Secretion of SDF-1 was detected in the cell basal medium of MCF-7. When adding a high physiological concentrations of 17-β estradiol (10(-7) mol/L), the levels of SDF-1 secretion achieved a peak at 2 h and it was 6 times of control group (1823.16 ± 325.18 pg/ml comparing to 308.23 ± 9.23 pg/ml, P < 0.01). However, this effect could be eliminated by the pure estrogen antagonist ICI182 or ICI780. The SDF-1 mRNA levels were consistent with the determined SDF-1 protein levels. At the time point of 2 h, for the 10(-7) mol/L group, the SDF-1 mRNA expression levels were higher than the antagonist group, with statistically significant differences (P < 0.05). CONCLUSIONS: It was found that secretion of SDF-1 can be increased by the physiological concentrations of estrogen mainly through regulation of estrogen receptor.
OBJECTIVE:Stromal cell derived factor-1 (SDF-1) is closely related to the biological characteristics of breast cancer. The aim of this article is to investigate if estrogen affects the biological characteristics of breast cancer via affecting secretion of SDF-1. METHODS: The breast cancer cell lines MCF-7 and MDA-MB-231 used in this study were divided into control group, estrogen group and estrogen plus estrogen receptor (ER) antagonist group. These groups were treated with different concentrations of 17-β estradiol or the same concentration of 17-β estradiol for different times, respectively. Enzyme-linked immunosorbent assay and semi-quantitative reverse transcriptase polymerase chain reaction were performed. RESULTS: Secretion of SDF-1 was detected in the cell basal medium of MCF-7. When adding a high physiological concentrations of 17-β estradiol (10(-7) mol/L), the levels of SDF-1 secretion achieved a peak at 2 h and it was 6 times of control group (1823.16 ± 325.18 pg/ml comparing to 308.23 ± 9.23 pg/ml, P < 0.01). However, this effect could be eliminated by the pure estrogen antagonist ICI182 or ICI780. The SDF-1 mRNA levels were consistent with the determined SDF-1 protein levels. At the time point of 2 h, for the 10(-7) mol/L group, the SDF-1 mRNA expression levels were higher than the antagonist group, with statistically significant differences (P < 0.05). CONCLUSIONS: It was found that secretion of SDF-1 can be increased by the physiological concentrations of estrogen mainly through regulation of estrogen receptor.
Entities:
Keywords:
17-βestradiol; Breast cancer; MCF-7; MDA-MB-231; SDF-1
Authors: Jonna Frasor; Edmund C Chang; Barry Komm; Chin-Yo Lin; Vinsensius B Vega; Edison T Liu; Lance D Miller; Johanna Smeds; Jonas Bergh; Benita S Katzenellenbogen Journal: Cancer Res Date: 2006-07-15 Impact factor: 12.701
Authors: Gerald E Stoica; Thomas F Franke; Maria Moroni; Susette Mueller; Elisha Morgan; Mary C Iann; Abigail D Winder; Ronald Reiter; Anton Wellstein; Mary Beth Martin; Adriana Stoica Journal: Oncogene Date: 2003-09-11 Impact factor: 9.867